Advances in the production and downstream processing of antibodies.

[1]  Lynn Conley,et al.  Downstream antibody purification using aqueous two‐phase extraction , 2010, Biotechnology progress.

[2]  C. Kontoravdi,et al.  Towards the implementation of quality by design to the production of therapeutic monoclonal antibodies with desired glycosylation patterns , 2010, Biotechnology progress.

[3]  Feng Li,et al.  Cell culture processes for monoclonal antibody production , 2010, mAbs.

[4]  Thomas Ryll,et al.  Maximizing productivity of CHO cell‐based fed‐batch culture using chemically defined media conditions and typical manufacturing equipment , 2010, Biotechnology progress.

[5]  Andrew J Racher,et al.  Strategies for selecting Recombinant CHO cell lines for cGMP manufacturing: Realizing the potential in bioreactors , 2010, Biotechnology progress.

[6]  Patrick Thompson,et al.  Defining process design space for monoclonal antibody cell culture , 2010, Biotechnology and bioengineering.

[7]  Y. Dorokhov,et al.  Transient expression systems for plant-derived biopharmaceuticals , 2010, Expert Review of Vaccines.

[8]  H. Vié,et al.  EB66 cell line, a duck embryonic stem cell-derived substrate for the industrial production of therapeutic monoclonal antibodies with enhanced ADCC activity , 2010, mAbs.

[9]  Michael W. Laird,et al.  Identification and prevention of antibody disulfide bond reduction during cell culture manufacturing , 2010, Biotechnology and bioengineering.

[10]  Abhinav A Shukla,et al.  Recent advances in large-scale production of monoclonal antibodies and related proteins. , 2010, Trends in biotechnology.

[11]  Niki S. C. Wong,et al.  Engineering mammalian cells in bioprocessing – current achievements and future perspectives , 2010, Biotechnology and applied biochemistry.

[12]  Takeshi Omasa,et al.  Cell engineering and cultivation of chinese hamster ovary (CHO) cells. , 2010, Current pharmaceutical biotechnology.

[13]  Marcus Taupp,et al.  Expression of recombinant proteins in the methylotrophic yeast Pichia pastoris. , 2010, Journal of visualized experiments : JoVE.

[14]  Mariana Henriques,et al.  Guidelines to cell engineering for monoclonal antibody production. , 2010, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[15]  Gregory Zarbis-Papastoitsis,et al.  Development of a polishing step using a hydrophobic interaction membrane adsorber with a PER.C6®‐derived recombinant antibody , 2010, Biotechnology and bioengineering.

[16]  Mariana Henriques,et al.  Technological progresses in monoclonal antibody production systems , 2009, Biotechnology progress.

[17]  Antonio Granell,et al.  Manufacturing antibodies in the plant cell , 2009, Biotechnology journal.

[18]  Yan Zhou,et al.  A high-yielding, generic fed-batch process for recombinant antibody production of GS-engineered cell lines. , 2009, Journal of microbiology and biotechnology.

[19]  Brian Kelley,et al.  Industrialization of mAb production technology: The bioprocessing industry at a crossroads , 2009, mAbs.

[20]  R. Jefferis,et al.  Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action. , 2009, Trends in pharmacological sciences.

[21]  Jianxin Ye,et al.  High‐level protein expression in scalable CHO transient transfection , 2009, Biotechnology and bioengineering.

[22]  Naoko Yamane-Ohnuki,et al.  Production of therapeutic antibodies with controlled fucosylation , 2009, mAbs.

[23]  E. Waltz.  Genentech's Cabilly victory , 2009, Nature Biotechnology.

[24]  Christel Fenge,et al.  Automation of cell line development , 2009, Cytotechnology.

[25]  J. Tramper,et al.  Effect of Feed and Bleed Rate on Hybridoma Cells in an Acoustic Perfusion Bioreactor: Metabolic Analysis , 2008, Biotechnology progress.

[26]  R. Jefferis.  Glycosylation of Recombinant Antibody Therapeutics , 2008, Biotechnology progress.

[27]  Emily Waltz.  Cabilly patent finale , 2008, Nature Biotechnology.

[28]  David E. Steinmeyer,et al.  The art of antibody process development. , 2008, Drug discovery today.

[29]  Uwe Gottschalk,et al.  Bioseparation in Antibody Manufacturing: The Good, The Bad and The Ugly , 2008, Biotechnology progress.

[30]  E. Waltz.  Four rebuffs for Cabilly , 2008, Nature Biotechnology.

[31]  T. Dingermann.  Recombinant therapeutic proteins: Production platforms and challenges , 2008, Biotechnology journal.

[32]  Y. Jigami,et al.  Production of humanized glycoproteins in bacteria and yeasts. , 2007, Current opinion in chemical biology.

[33]  Shigeru Iida,et al.  Double knockdown of α1,6-fucosyltransferase (FUT8) and GDP-mannose 4,6-dehydratase (GMD) in antibody-producing cells: a new strategy for generating fully non-fucosylated therapeutic antibodies with enhanced ADCC , 2007, BMC Biotechnology.

[34]  R. Scheller.  Why Cabilly must stand , 2007, Nature Biotechnology.

[35]  J. Carton,et al.  Codon engineering for improved antibody expression in mammalian cells. , 2007, Protein expression and purification.

[36]  Morrow Kj.  Antibody World Summit 2007--SRI's Sixth Annual Meeting. Discovery & development/manufacturing & processing. 16-17 July 2007, New Brunswick, NJ, USA. , 2007 .

[37]  K. Maggon,et al.  Monoclonal antibody "gold rush". , 2007, Current medicinal chemistry.

[38]  E. Waltz.  Industry waits for fallout from Cabilly , 2007, Nature Biotechnology.

[39]  R. Werner,et al.  Glycosylation of therapeutic proteins in different production systems , 2007, Acta paediatrica.

[40]  Suzanne S Farid,et al.  Process economics of industrial monoclonal antibody manufacture. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[41]  Paul W. Sauer,et al.  Derivation and characterization of cholesterol‐independent non‐GS NS0 cell lines for production of recombinant antibodies , 2007, Biotechnology and bioengineering.

[42]  Weichang Zhou,et al.  Protein‐free fed‐batch culture of non‐GS NS0 cell lines for production of recombinant antibodies , 2007, Biotechnology and bioengineering.

[43]  Brigitte Gasser,et al.  Antibody production with yeasts and filamentous fungi: on the road to large scale? , 2007, Biotechnology Letters.

[44]  P. Salmon,et al.  A novel function for selenium in biological system: Selenite as a highly effective iron carrier for Chinese hamster ovary cell growth and monoclonal antibody production , 2006, Biotechnology and bioengineering.

[45]  Steven Kozlowski,et al.  Current and future issues in the manufacturing and development of monoclonal antibodies. , 2006, Advanced drug delivery reviews.

[46]  Klaus Graumann,et al.  Manufacturing of recombinant therapeutic proteins in microbial systems , 2006, Biotechnology journal.

[47]  Johannes Tramper,et al.  Stable hybridoma cultivation in a pilot-scale acoustic perfusion system: long-term process performance and effect of recirculation rate. , 2005, Biotechnology and bioengineering.

[48]  Keith L Carson.  Flexibility—the guiding principle for antibody manufacturing , 2005, Nature Biotechnology.

[49]  L. Álvarez-Vallina,et al.  Antibody engineering: facing new challenges in cancer therapy , 2005, Acta Pharmacologica Sinica.

[50]  K. Jooss,et al.  Stable antibody expression at therapeutic levels using the 2A peptide , 2005, Nature Biotechnology.

[51]  Johannes Tramper,et al.  Effect of feed and bleed rate on hybridoma cells in an acoustic perfusion bioreactor: part I. Cell density, viability, and cell-cycle distribution. , 2004, Biotechnology and bioengineering.

[52]  H. Mellstedt,et al.  Development of a technology platform for large-scale clinical grade production of DC. , 2004, Cytotherapy.

[53]  S. Schillberg,et al.  Production of therapeutic antibodies in plants , 2003, Expert opinion on biological therapy.

[54]  L. Houdebine.  Antibody manufacture in transgenic animals and comparisons with other systems , 2002, Current Opinion in Biotechnology.

[55]  J. Sidney,et al.  Rationally engineered proteins or antibodies with absent or reduced immunogenicity. , 2002, Current medicinal chemistry.

[56]  S. Morrison,et al.  Myeloma expression systems. , 2002, Journal of immunological methods.

[57]  M Vanderlaan,et al.  Industrial Purification of Pharmaceutical Antibodies: Development, Operation, and Validation of Chromatography Processes , 2001, Biotechnology & genetic engineering reviews.

[58]  J. D. Yang,et al.  Achievement of high cell density and high antibody productivity by a controlled-fed perfusion bioreactor process. , 2000, Biotechnology and bioengineering.

[59]  R. Hamilton,et al.  Humanized antibodies as potential therapeutic drugs. , 1998, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[60]  W. Noé,et al.  Appropriate mammalian expression systems for biopharmaceuticals. , 1998, Arzneimittel-Forschung.

[61]  R Hjorth,et al.  Expanded-bed adsorption in industrial bioprocessing: recent developments. , 1997, Trends in biotechnology.

[62]  Pete Gagnon,et al.  How to Choose an Industrial Cation Exchanger for IgG Purification , 2010 .

[63]  J. Chon,et al.  Primary Clarification of Very High-Density Cell Culture Harvests By Enhanced Cell Settling , 2010 .

[64]  J. Tanha,et al.  Isolation of monoclonal antibody fragments from phage display libraries. , 2009, Methods in molecular biology.

[65]  K. Ko,et al.  Production of antibodies in plants: approaches and perspectives. , 2009, Current topics in microbiology and immunology.

[66]  J. M. Coco-Martin,et al.  A review of therapeutic protein expression by mammalian cells , 2008 .

[67]  Ashok Kumar,et al.  Upstream processes in antibody production: evaluation of critical parameters. , 2008, Biotechnology advances.

[68]  K John Morrow,et al.  Advances in antibody manufacturing using mammalian cells. , 2007, Biotechnology annual review.

[69]  A. Arunakumari,et al.  Improved downstream process design for human monoclonal antibody production : A two-step process-a cation exchange capture column followed by anion exchange flow-through membrane chromatography-resulted in >80% process yield, higher batch capacity, and shorter process time , 2007 .

[70]  Brian Kelley,et al.  Very Large Scale Monoclonal Antibody Purification: The Case for Conventional Unit Operations , 2007, Biotechnology progress.

[71]  Sunil Chhatre,et al.  The Integrated Simulation and Assessment of the Impacts of Process Change in Biotherapeutic Antibody Production , 2006, Biotechnology progress.

[72]  Joe X. Zhou,et al.  Basic Concepts in Q Membrane Chromatography for Large‐Scale Antibody Production , 2006, Biotechnology progress.

[73]  R. Sodoyer,et al.  Anticorps monoclonaux et recombinants, 30 ans déjà... , 2006 .

[74]  S. Kipriyanov,et al.  Generation and production of engineered antibodies , 2004, Molecular biotechnology.

[75]  T. Logtenberg,et al.  High‐Level Expression of Recombinant IgG in the Human Cell Line PER.C6 , 2003, Biotechnology progress.

[76]  D. Siegel.  Recombinant monoclonal antibody technology. , 2002, Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine.